

B Heparin-II binding domain of fibronectin having an amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala
Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr Pro Lys Glu
Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser
Gly Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu
Thr Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro Arg
Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr
Glu Thr Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr Pro Ile Gln
Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp
Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp
Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr Pro Asn
Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr
Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu
Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys
Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind retroviruses.

93. The cellular population of claim 92, wherein said recombinant polypeptide is recombinant fibronectin fragment selected from the group consisting of CH-296 and H-296.

REMARKS

Entry of the above amendments is requested. Upon entry of the amendments, this application will contain claims 11-93. These amendments introduce no new subject matter to the application. The majority of the new claims are closely drawn from corresponding claims in the grandparent (PCT) application. New claims have been added directed to the recombinant polypeptide being selected from certain recombinant fibronectin polypeptides (e.g. CH-296, etc.). These claims are supported for example at page 16 of the application and in the specific Examples in which these recombinant


U.S. Serial No. 09/394,565
Inventor: David A. Williams
Group Art Unit 1636

polypeptides are employed. New claims have also been added directed to the use of mammalian cells as target cells. These claims are supported throughout the application in which mammalian cells are identified and employed and specifically for example in the Summary where "mammalian cells" are identified as targets for efficient retroviral infection in accordance with the invention.

Favorable consideration of the amended claims is solicited.

Respectfully submitted,

By


Kenneth A. Gandy
Reg. No. 33,386

Woodard, Emhardt, Naughton,
Moriarty & McNett

Bank One Center/Tower, Suite 3700
111 Monument Circle
Indianapolis, Indiana 46204-5137

(317) 634-3456